StockNow
Log in
U.S. MarketsIMPORTANT

Merck & Co. Inc. (MRK) Q2 2026 (USD) Adj. EPS -0.13 (exp. -0.27), Revenue 16.6bln (exp. 16.37bln), Current FY EPS 2.66-2.76 (exp. 2.76), Current FY Rev. 66.3-67.3bln (exp. 66.83bln)

StockNow breaking-news AI analysis

Merck delivered a Q2 revenue and EPS beat, driven by strong growth in WINREVAIR and KEYTRUDA QLEX, despite lowering full-year EPS guidance due to acquisition-related one-time costs.

News detail

Total Worldwide Sales USD 16.6bln (5% Growth; 4% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX1 Sales USD 8.4bln (5% Growth; 4% Growth ex-FX); Includes KEYTRUDA QLEX Sales of USD 463mln WINREVAIR Sales USD 588mln (75% Growth; 75% Growth ex-FX) Animal Health Sales USD 1.8bln (8% Growth; 5% Growth ex-FX)

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)